-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: venture funding
Biotech Hall of Fame: Interview with Biotech’s First Investment Banker
Earlier this week, I had the opportunity to discuss biotech’s storied history with Fred Frank, one of the industry’s greatest luminaries, on what we can learn from the past to help shape the future. Fred Frank, formerly Vice Chairman of both Lehman Brothers Inc. and Peter J. Solomon Company, recently became Vice Chairman of Burrill & Company and Chairman of Burrill Securities, the broker dealer arm of Burrill & Company. He was the first life Read More >
Big Ventures
It is rare to see triple digit millions in private financing rounds, but it does happen once or twice a year on average. In the headlines last week, was the largest triple digit VC round in years – the $160M in venture capital funding for Intarcia. With the simultaneous debt financing of $50M, the total funding round was $210M. Behind the deal were existing investors New Enterprise Associates, New Leaf Venture Partners and Venrock, plus Read More >
BIO Europe Spring 2012 – Opening Remarks
For Monday’s Opening Remarks at BIO Europe Spring 2012, I covered the following topics: Public market performance in the US vs other sectors Private funding environment. Drug pipeline deal volume. For a copy of the slides, they can be found here.
Inside BIO Industry Analysis
Leave a comment
Email This Post
Tags: BIO Europe, deals, Industry Analysis, opening remarks, orphan, Partnering, Partnering Stats, PowerPoint, PRIVATE BIOTECH, PUBLIC BIOTECH - Stats, PUBLIC BIOTECH - Stock performance, public sector research, Venture Capital, venture financing, venture funding
Tags: BIO Europe, deals, Industry Analysis, opening remarks, orphan, Partnering, Partnering Stats, PowerPoint, PRIVATE BIOTECH, PUBLIC BIOTECH - Stats, PUBLIC BIOTECH - Stock performance, public sector research, Venture Capital, venture financing, venture funding
Medical Innovation at Risk
The National Venture Capital Association’s MedIC Coalition recently released a report showing U.S. venture capitalists are decreasing their investments in biopharmaceutical and medical device companies, reducing their concentration in prevalent disease areas and shifting investments towards Europe and Asia. The report, Vital Signs: The Threat to Investment in U.S. Medical Innovation and the Imperative of FDA Reform, strongly indicates that America’s medical innovation economy is in grave danger of losing its primary source of funding, Read More >
Unleashing the Promise of Biotechnology to Cure Disease and Save Lives
The other day I came across an article discussing vaccinations and the author mentioned his 15-year-old son asking him: “Dad, what’s polio?” Many of us are old enough to remember a time when polio struck fear and caused suffering for millions. Today, at least in the developed world, polio is something kids have to ask their parents to explain to them. Imagine someday, our grandchildren asking us, “What was cancer?” How great would that be? Read More >
